{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:08:27Z","timestamp":1788948507990,"version":"build-2803163510"},"reference-count":182,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>The hepatocyte growth factor (HGF)\/c-Met signaling pathway plays a central role in cellular proliferation, survival, migration, invasion, angiogenesis, and therapeutic resistance. Aberrant c-Met activation, driven by gene amplification, overexpression, activating mutations, exon 14-skipping alterations, or ligand-dependent stimulation, drives the development and progression of many solid tumors, positioning c-Met as a key target for anticancer drug development. The clinical effectiveness of c-Met-targeted treatments such as crizotinib, capmatinib, tepotinib, savolitinib, and cabozantinib has confirmed c-Met as a viable oncogenic driver for therapy, leading to the development of various next-generation inhibitors with different structures. This review provides a comprehensive perspective on small-molecule c-Met inhibitors from the perspectives of medicinal chemistry and structure-based drug design, encompassing approved drugs, investigational agents, natural-product-inspired leads, and emerging multitarget anticancer therapeutics. Particular emphasis is given to the principles of molecular recognition that govern c-Met inhibition. This includes the structure of the kinase domain, interactions at the ATP-binding site, recognition of the hinge region, and the different binding modes of Type I, Type II, and allosteric inhibitors. The design, synthesis, biological evaluation, and structure\u2013activity relationships of diverse heterocyclic scaffolds that have shaped c-Met inhibitor discovery are critically analyzed. Key medicinal chemistry strategies, including scaffold hopping, bioisosteric replacement, conformational optimization, molecular hybridization, and multitarget pharmacophore integration, are discussed in the context of potency, selectivity, resistance management, and drug-like properties. Particular attention is given to the integration of structural biology, molecular docking, binding-mode analysis, and structure-guided optimization approaches that have enabled the development of potent c-Met-directed inhibitors. In addition, recent advances in dual- and multitarget agents that simultaneously modulate c-Met and complementary therapeutic targets, including VEGFR-2, EGFR, AXL, MER, PARP1, CDK2, and tubulin, are highlighted as promising strategies for overcoming pathway redundancy and acquired resistance. This review summarizes contemporary structure-based and medicinal chemistry principles underlying c-Met inhibitor discovery, critically evaluates the relationship between biochemical potency and therapeutic efficacy, and provides a framework for the rational design of next-generation c-Met-targeted and multitarget anticancer agents.<\/jats:p>","DOI":"10.3390\/ijms27188007","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T09:24:02Z","timestamp":1788945842000},"page":"8007","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Medicinal Chemistry of Small-Molecule c-Met Inhibitors: From Approved Therapies to Emerging Multitarget Anticancer Agents"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3668-104X","authenticated-orcid":false,"given":"Siva S.","family":"Panda","sequence":"first","affiliation":[{"name":"Department of Chemistry and Biochemistry, Augusta University, Augusta, GA 30912, USA"},{"name":"Department of Biochemistry and Molecular Biology, Augusta University, Augusta, GA 30912, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed S.","family":"Bekheit","sequence":"additional","affiliation":[{"name":"Department of Pesticide Chemistry, National Research Centre, Dokki, Giza 12622, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0038-0835","authenticated-orcid":false,"given":"Dalia R.","family":"Aboshouk","sequence":"additional","affiliation":[{"name":"Department of Pesticide Chemistry, National Research Centre, Dokki, Giza 12622, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhan","family":"Sivakumar","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Biochemistry, Augusta University, Augusta, GA 30912, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Morsy","sequence":"additional","affiliation":[{"name":"Al-Azhar Virology Research Center, Faculty of Medicine, Al-Azhar University, Cairo 71524, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Abdur-Rahman","sequence":"additional","affiliation":[{"name":"Chemistry Department, Faculty of Science, Cairo University, Giza 12613, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelgawad","family":"Fahmi","sequence":"additional","affiliation":[{"name":"Chemistry Department, Faculty of Science, Cairo University, Giza 12613, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4407-9745","authenticated-orcid":false,"given":"Adel S.","family":"Girgis","sequence":"additional","affiliation":[{"name":"Department of Pesticide Chemistry, National Research Centre, Dokki, Giza 12622, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"103970","DOI":"10.1016\/j.bioorg.2020.103970","article-title":"Discovery of novel dual c-Met\/HDAC inhibitors as a promising strategy for cancer therapy","volume":"101","author":"Hu","year":"2020","journal-title":"Bioorg. Chem."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"113768","DOI":"10.1016\/j.ejmech.2021.113768","article-title":"Molecular hybrids: A five-year survey on structures of multiple targeted hybrids of protein kinase inhibitors for cancer therapy","volume":"225","author":"Soltan","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ceb.2007.02.010","article-title":"Receptor tyrosine kinases: Mechanisms of activation and signaling","volume":"19","author":"Hubbard","year":"2007","journal-title":"Curr. Opin. Cell Biol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"115166","DOI":"10.1016\/j.jpba.2022.115166","article-title":"Screening assays for tyrosine kinase inhibitors: A review","volume":"223","author":"Gao","year":"2023","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5619","DOI":"10.1021\/ja100862u","article-title":"Design of an encodable tyrosine kinase-inducible domain: Detection of tyrosine kinase activity by terbium luminescence","volume":"132","author":"Zondlo","year":"2010","journal-title":"J. Am. Chem. Soc."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"105466","DOI":"10.1016\/j.bioorg.2021.105466","article-title":"Synthesis of aspirin-curcumin mimic conjugates of potential antitumor and anti-SARS-CoV-2 properties","volume":"117","author":"Srour","year":"2021","journal-title":"Bioorg. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"13880","DOI":"10.1038\/s41598-022-17883-9","article-title":"Development of spiro-3-indolin-2-one containing compounds of antiproliferative and anti-SARS-CoV-2 properties","volume":"12","author":"Fawazy","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"114215","DOI":"10.1016\/j.ejmech.2022.114215","article-title":"Synthesis, bioevaluation and molecular dynamics of pyrrolo-pyridine benzamide derivatives as potential antitumor agents in vitro and in vivo","volume":"233","author":"Zhang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00044-022-02986-9","article-title":"Design, synthesis, and biological evaluation of 2,4-dichlorophenoxyacetamide chalcone hybrids as potential c-Met kinase inhibitors","volume":"32","author":"Bhojwani","year":"2023","journal-title":"Med. Chem. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1002\/cjoc.202100106","article-title":"Design, synthesis and biological evaluation of novel \u03b1-acyloxycarboxamide-based derivatives as c-Met inhibitors","volume":"39","author":"Feng","year":"2021","journal-title":"Chin. J. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"118497","DOI":"10.1016\/j.bmc.2025.118497","article-title":"Unveiling the power of quinazoline derivatives: A new frontier in targeted cancer therapy","volume":"133","author":"Long","year":"2026","journal-title":"Bioorg. Med. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e01396","DOI":"10.1002\/cbdv.202501396","article-title":"Medicinal chemistry perspective of 1,8-naphthyridines as anticancer agents","volume":"22","author":"Trivedi","year":"2025","journal-title":"Chem. Biodivers."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"118027","DOI":"10.1016\/j.ejmech.2025.118027","article-title":"Targeting the HGF\/MET axis in cancer: Therapeutic promise for natural compounds","volume":"298","author":"Goleij","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"117177","DOI":"10.1016\/j.ejmech.2024.117177","article-title":"Advances in the selective c-MET kinase inhibitors: Application of fused [5,6]-bicyclic nitrogen-containing cores for anticancer drug design","volume":"284","author":"Valipour","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"116477","DOI":"10.1016\/j.ejmech.2024.116477","article-title":"Recent advances in c-Met-based dual inhibitors in the treatment of cancers","volume":"272","author":"Jin","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1021\/acsomega.3c04749","article-title":"Structure-activity relationship study and design strategies of hydantoin, thiazolidinedione, and rhodanine-based kinase inhibitors: A two-decade review","volume":"9","author":"Naufal","year":"2024","journal-title":"ACS Omega"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Nitulescu, G.M., Stancov, G., Seremet, O.C., Nitulescu, G., Mihai, D.P., Duta-Bratu, C.G., Barbuceanu, S.F., and Olaru, O.T. (2023). The importance of the pyrazole scaffold in the design of protein kinases inhibitors as targeted anticancer therapies. Molecules, 28.","DOI":"10.3390\/molecules28145359"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"106425","DOI":"10.1016\/j.bioorg.2023.106425","article-title":"Recent development of multi-target VEGFR-2 inhibitors for the cancer therapy","volume":"133","author":"Liu","year":"2023","journal-title":"Bioorg. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"105672","DOI":"10.1016\/j.bioorg.2022.105672","article-title":"Design, synthesis and anticancer evaluation of 6,7-disubstituted-4-phenoxyquinoline derivatives bearing 1,8-naphthyridine-3-carboxamide moiety as novel multi-target TKIs","volume":"121","author":"Chen","year":"2022","journal-title":"Bioorg. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"105304","DOI":"10.1016\/j.bioorg.2021.105304","article-title":"Transforming Type II to Type I c-Met kinase inhibitors via combined scaffold hopping and structure-guided synthesis of new series of 1,3,4-thiadiazolo[2,3-c]-1,2,4-triazin-4-one derivatives","volume":"116","author":"Teleb","year":"2021","journal-title":"Bioorg. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s11030-020-10067-5","article-title":"Synthesis of triazolotriazine derivatives as c-Met inhibitors","volume":"25","author":"Guo","year":"2021","journal-title":"Mol. Divers."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"105629","DOI":"10.1016\/j.bioorg.2022.105629","article-title":"Novel 4-phenoxypyridine derivatives bearing imidazole-4-carboxamide and 1,2,4-triazole-3-carboxamide moieties: Design, synthesis and biological evaluation as potent antitumor agents","volume":"120","author":"Liu","year":"2022","journal-title":"Bioorg. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1016\/j.drudis.2022.04.002","article-title":"Web support for the more efficient discovery of kinase inhibitors","volume":"27","author":"Chen","year":"2022","journal-title":"Drug Discov. Today"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1158\/1535-7163.MCT-21-0344","article-title":"Combination of type I and type II MET tyrosine kinase inhibitors as therapeutic approach to prevent resistance","volume":"21","author":"Bahcall","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1158\/1078-0432.CCR-19-3608","article-title":"Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors in patients with MET exon 14\u2013mutant NSCLC","volume":"26","author":"Recondo","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"6926","DOI":"10.1038\/s41598-025-85631-w","article-title":"Molecular mechanism of type ib MET inhibitors and their potential for CNS tumors","volume":"15","author":"Liu","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Ji, M., Ganesan, S., Xia, B., and Huo, Y. (2025). Targeting c-MET alterations in cancer: A review of genetic drivers and therapeutic implications. Cancers, 17.","DOI":"10.3390\/cancers17091493"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41591-019-0716-8","article-title":"Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration","volume":"26","author":"Drilon","year":"2020","journal-title":"Nat. Med."},{"key":"ref_30","unstructured":"(2026, June 10). Xalkori (Crizotinib) FDA Approval History\u2014Drugs.com. Available online: https:\/\/www.drugs.com\/history\/xalkori.html."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1750-9378-8-13","article-title":"c-Met inhibitors","volume":"8","author":"Mughal","year":"2013","journal-title":"Infect. Agents Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/aps.2010.106","article-title":"Potential therapeutics specific to c-MET\/RON receptor tyrosine kinases for molecular targeting in cancer therapy","volume":"31","author":"Wang","year":"2010","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1158\/1078-0432.CCR-14-3258","article-title":"The c-Met tyrosine kinase inhibitor JNJ-38877605 causes renal toxicity through species specific insoluble metabolite formation","volume":"21","author":"Lolkema","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_34","unstructured":"Uses, Interactions, Mechanism of Action\u2014DrugBank (Standard No. JNJ-38877605). Available online: https:\/\/go.drugbank.com\/drugs\/DB13113."},{"key":"ref_35","unstructured":"(2026, June 10). MK-2461\u2014C-Met Inhibitor\u2014MedChemExpress. Available online: https:\/\/www.medchemexpress.com\/MK-2461.html."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1158\/0008-5472.CAN-09-2541","article-title":"MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor","volume":"70","author":"Pan","year":"2010","journal-title":"Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"11218","DOI":"10.1074\/jbc.M110.204404","article-title":"Structural basis for selective small molecule kinase inhibition of activated c-Met","volume":"286","author":"Rickert","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2147\/LCTT.S360574","article-title":"Spotlight on tepotinib and capmatinib for non-small cell lung cancer with MET exon 14 skipping mutation","volume":"13","author":"Brazel","year":"2022","journal-title":"Lung Cancer Targets Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13045-022-01299-z","article-title":"Foretinib can overcome common on-target resistance mutations after capmatinib\/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation","volume":"15","author":"Fujino","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_40","unstructured":"(2026, June 10). Capmatinib: Uses, Interactions, Mechanism of Action\u2014DrugBank. Available online: https:\/\/go.drugbank.com\/drugs\/DB11791."},{"key":"ref_41","unstructured":"(2026, June 10). Tabrecta (Capmatinib) FDA Approval History\u2014Drugs.com. Available online: https:\/\/www.drugs.com\/history\/tabrecta.html."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2147\/LCTT.S547090","article-title":"A concise review of the approved MET TKIs (savolitinib, gumarontinib, vebreltinib, tepotinib, capmatinib) in China for MET exon 14 splice site mutated (METex14+) NSCLC Circa 2025","volume":"16","author":"Hu","year":"2025","journal-title":"Lung Cancer Targets Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"101983","DOI":"10.1016\/j.xcrm.2025.101983","article-title":"The expanding role of the receptor tyrosine kinase MET as a therapeutic target in non-small cell lung cancer","volume":"6","author":"Sattler","year":"2025","journal-title":"Cell Rep. Med."},{"key":"ref_44","unstructured":"(2026, June 10). Tepotinib: Uses, Interactions, Mechanism of Action\u2014DrugBank. Available online: https:\/\/go.drugbank.com\/drugs\/DB15133."},{"key":"ref_45","unstructured":"(2026, June 10). Tepmetko (Tepotinib) FDA Approval History\u2014Drugs.com. Available online: https:\/\/www.drugs.com\/history\/tepmetko.html."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"RP101882","DOI":"10.7554\/eLife.101882","article-title":"Mapping kinase domain resistance mechanisms for the MET receptor tyrosine kinase via deep mutational scanning","volume":"13","author":"Estevam","year":"2025","journal-title":"eLife"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Fu, M., Feng, C.-M., Xia, D.-Q., Ji, Z.-M., Xia, H.-L., Hu, N.-N., Leng, Z.-J., Xie, W., Fang, Y., and Cao, L.-J. (2022). Neoadjuvant Savolitinib targeted therapy stage IIIA-N2 primary lung adenocarcinoma harboring MET Exon 14 skipping mutation: A case report. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.954886"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Lee, T.S., Kim, J.Y., Lee, M.H., Cho, I.R., Paik, W.H., Ryu, J.K., Kim, Y.-T., and Lee, S.H. (2023). Savolitinib: A promising targeting agent for cancer. Cancers, 15.","DOI":"10.3390\/cancers15194708"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1007\/s40265-021-01584-0","article-title":"Savolitinib: First approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"ref_50","unstructured":"(2026, June 10). Savolitinib: Uses, Interactions, Mechanism of Action\u2014DrugBank. Available online: https:\/\/go.drugbank.com\/drugs\/DB12048."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s00432-025-06115-y","article-title":"Advances in clinical research of MET exon 14 skipping mutations in non-small cell lung cancer","volume":"151","author":"Wang","year":"2025","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_52","unstructured":"(2026, June 10). Vebreltinib: Uses, Interactions, Mechanism of Action\u2014DrugBank. Available online: https:\/\/go.drugbank.com\/drugs\/DB16823."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Spagnolo, C.C., Ciappina, G., Giovannetti, E., Squeri, A., Granata, B., Lazzari, C., Pretelli, G., Pasello, G., and Santarpia, M. (2023). Targeting MET in non-small cell lung cancer (NSCLC): A new old story?. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241210119"},{"key":"ref_54","unstructured":"(2026, June 10). Glumetinib: Uses, Interactions, Mechanism of Action\u2014DrugBank. Available online: https:\/\/go.drugbank.com\/drugs\/DB15630."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"18693","DOI":"10.18632\/oncotarget.4472","article-title":"A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors","volume":"6","author":"Hong","year":"2015","journal-title":"Oncotarget"},{"key":"ref_56","unstructured":"(2026, June 10). Amg-208\u2014C22H17N5O2\u2014CID 24864821\u2014PubChem\u2014NIH, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/amg-208."},{"key":"ref_57","unstructured":"(2026, June 10). AMG-208: Uses, Interactions, Mechanism of Action\u2014DrugBank. Available online: https:\/\/go.drugbank.com\/drugs\/DB08079."},{"key":"ref_58","unstructured":"(2026, June 10). Cabozantinib, Uses, Interactions, Mechanism of Action\u2014DrugBank. Available online: https:\/\/go.drugbank.com\/drugs\/DB08875."},{"key":"ref_59","unstructured":"(2026, June 10). Cabometyx (Cabozantinib) FDA Approval History\u2014DrugBank. Available online: https:\/\/www.drugs.com\/history\/cabometyx.html."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1021\/acsmedchemlett.9b00276","article-title":"Structural and molecular insight into resistance mechanisms of first generation cMET inhibitors","volume":"10","author":"Collie","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1158\/1078-0432.CCR-10-0574","article-title":"A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2","volume":"16","author":"Eder","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Shah, M.A., Wainberg, Z.A., Catenacci, D.V.T., Hochster, H.S., Ford, J., Kunz, P., Lee, F.-C., Kallender, H., Cecchi, F., and Rabe, D.C. (2013). Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET\/VEGFR2 inhibitor, in patients with metastatic gastric cancer. PLoS ONE, 8, Correction in PLoS ONE 2022, 17, e0276211. https:\/\/doi.org\/10.1371\/journal.pone.0276211.","DOI":"10.1371\/journal.pone.0276211"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Zhang, Q., Zheng, P., and Zhu, W. (2020). Research progress of small molecule VEGFR\/c-Met inhibitors as anticancer agents (2016\u2013Present). Molecules, 25.","DOI":"10.3390\/molecules25112666"},{"key":"ref_64","unstructured":"(2026, June 10). Foretinib: Uses, Interactions, Mechanism of Action\u2014DrugBank. Available online: https:\/\/go.drugbank.com\/drugs\/DB12307."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Arnold, L., Enders, J., and Thomas, S.M. (2017). Activated HGF-c-Met axis in head and neck cancer. Cancers, 9.","DOI":"10.3390\/cancers9120169"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Huang, T.-T., Chen, C.-M., Lan, Y.-W., Lin, S.-S., Choo, K.-B., and Chong, K.-Y. (2022). Blockade of c-Met-mediated signaling pathways by E7050 suppresses growth and promotes apoptosis in multidrug-resistant human uterine sarcoma cells. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232314884"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Huang, T.-T., Chen, C.-M., Lin, S.-S., Lan, Y.-W., Cheng, H.-C., Choo, K.-B., Wang, C.-C., Huang, T.-H., and Chong, K.-Y. (2023). E7050 suppresses the growth of multidrug-resistant human uterine sarcoma by inhibiting angiogenesis via targeting of VEGFR2-mediated signaling pathways. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24119606"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"90557","DOI":"10.18632\/oncotarget.21164","article-title":"Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer","volume":"8","author":"Xu","year":"2017","journal-title":"Oncotarget"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.ejmech.2015.12.016","article-title":"Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs","volume":"108","author":"Zhang","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_70","unstructured":"(2026, June 10). Golvatinib: Uses, Interactions, Mechanism of Action\u2014DrugBank. Available online: https:\/\/go.drugbank.com\/drugs\/DB11977."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s10637-012-9912-9","article-title":"LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models","volume":"31","author":"Yan","year":"2012","journal-title":"Investig. New Drugs"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1007\/s10637-017-0545-x","article-title":"MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping","volume":"36","author":"Yan","year":"2017","journal-title":"Investig. New Drugs"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"13796","DOI":"10.18632\/oncotarget.24488","article-title":"Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors","volume":"9","author":"Konicek","year":"2018","journal-title":"Oncotarget"},{"key":"ref_74","unstructured":"(2026, June 10). Merestinib: Uses, Interactions, Mechanism of Action\u2014DrugBank. Available online: https:\/\/go.drugbank.com\/drugs\/DB12381."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"6661","DOI":"10.1158\/1078-0432.CCR-17-1192","article-title":"Glesatinib exhibits antitumor activity in lung cancer models and patients harboring MET exon 14 mutations and overcomes mutation-mediated resistance to type I MET inhibitors in nonclinical models","volume":"23","author":"Engstrom","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s11523-022-00931-9","article-title":"Phase I study evaluating glesatinib (MGCD265), An inhibitor of MET and AXL, in patients with non-small cell lung cancer and other advanced solid tumors","volume":"18","author":"Kollmannsberger","year":"2022","journal-title":"Target. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.lungcan.2016.11.011","article-title":"The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The why, the how, the who, the unknown, and the inevitable","volume":"103","author":"Reungwetwattana","year":"2017","journal-title":"Lung Cancer"},{"key":"ref_78","unstructured":"(2026, June 10). Glesatinib: Uses, Interactions, Mechanism of Action\u2014DrugBank. Available online: https:\/\/go.drugbank.com\/drugs\/DB06302."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1158\/1535-7163.MCT-13-0075","article-title":"S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab","volume":"12","author":"Burbridge","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1158\/1535-7163.MCT-17-0112","article-title":"The MET\/AXL\/FGFR inhibitor S49076 impairs Aurora B activity and improves the antitumor efficacy of radiotherapy","volume":"16","author":"Chargari","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Sarukhanyan, E., Shityakov, S., and Dandekar, T. (2020). Rational drug design of Axl tyrosine kinase type I inhibitors as promising candidates against cancer. Front. Chem., 7.","DOI":"10.3389\/fchem.2019.00920"},{"key":"ref_82","unstructured":"(2026, June 10). S-49076: Uses, Interactions, Mechanism of Action\u2014DrugBank. Available online: https:\/\/go.drugbank.com\/drugs\/DB16821."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.molonc.2013.12.014","article-title":"Prevention of BMS-777607-induced polyploidy\/senescence by mTOR inhibitor AZD8055 sensitizes breast cancer cells to cytotoxic chemotherapeutics","volume":"8","author":"Sharma","year":"2014","journal-title":"Mol. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ejmech.2014.04.056","article-title":"Discovery of novel type II c-Met inhibitors based on BMS-777607","volume":"80","author":"Zhang","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"eaai9338","DOI":"10.1126\/scitranslmed.aai9338","article-title":"RON kinase: A target for treatment of cancer-induced bone destruction and osteoporosis","volume":"9","author":"Andrade","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1158\/2767-9764.CRC-23-0631","article-title":"Coordinated targeting of S6K1\/2 and AXL disrupts pyrimidine biosynthesis in PTEN-deficient glioblastoma","volume":"4","author":"Behrmann","year":"2024","journal-title":"Cancer Res. Commun."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e1480286","DOI":"10.1080\/2162402X.2018.1480286","article-title":"Inhibition of RON kinase potentiates anti-CTLA-4 immunotherapy to shrink breast tumors and prevent metastatic outgrowth","volume":"7","author":"Ekiz","year":"2018","journal-title":"OncoImmunology"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Koehler, A., Karve, A., Desai, P., Arbiser, J., Plas, D.R., Qi, X., Read, R.D., Sasaki, A.T., Gawali, V.S., and Toukam, D.K. (2021). Reuse of molecules for glioblastoma therapy. Pharmaceuticals, 14.","DOI":"10.3390\/ph14020099"},{"key":"ref_89","unstructured":"(2026, June 10). BMS-777607: Uses, Interactions, Mechanism of Action\u2014DrugBank. Available online: https:\/\/go.drugbank.com\/drugs\/DB12064."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Fujita, H., Miyadera, K., Ito, K., Takenaka, T., Huang, J., Ito, S., Suzuki, T., Ochiiwa, H., Egami, K., and Suefuji, T. (2011). Abstract 3577: TAS-115: A highly potent c-Met + VEGFRs dual inhibitor with prominently safer profile. Cancer Res., 71.","DOI":"10.1158\/1538-7445.AM2011-3577"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Fujita, H., Gomori, A., Fujioka, Y., Kataoka, Y., Tanaka, K., Hashimoto, A., Suzuki, T., Ito, K., Haruma, T., and Yamamoto-Yokoi, H. (2016). High potency VEGFRs\/MET\/FMS triple blockade by TAS-115 concomitantly suppresses tumor progression and bone destruction in tumor-induced bone disease model with lung carcinoma cells. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0164830"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Yamada, S., Imura, Y., Nakai, T., Nakai, S., Yasuda, N., Kaneko, K., Outani, H., Takenaka, S., Hamada, K., and Myoui, A. (2017). Therapeutic potential of TAS-115 via c-MET and PDGFR\u03b1 signal inhibition for synovial sarcoma. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3324-3"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Xiong, H., Cheng, J., Zhang, J., Zhang, Q., Xiao, Z., Zhang, H., Tang, Q., and Zheng, P. (2019). Design, synthesis, and biological evaluation of pyridineamide derivatives containing a 1,2,3-triazole fragment as type II c-Met inhibitors. Molecules, 25.","DOI":"10.3390\/molecules25010010"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"100511","DOI":"10.1016\/j.jbo.2023.100511","article-title":"Tyrosine kinase inhibitors in osteosarcoma: Adapting treatment strategiesa","volume":"43","author":"Assi","year":"2023","journal-title":"J. Bone Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s10637-019-00859-4","article-title":"Phase I study of TAS-115, a novel oral multi-kinase inhibitor, in patients with advanced solid tumors","volume":"38","author":"Doi","year":"2019","journal-title":"Investig. New Drugs"},{"key":"ref_96","first-page":"799","article-title":"Landscape and perspectives of macrophage-targeted cancer therapy in clinical trials","volume":"24","author":"Wang","year":"2022","journal-title":"MTO"},{"key":"ref_97","unstructured":"(2026, June 10). Pamufetinib: Uses, Interactions, Mechanism of Action\u2014DrugBank. Available online: https:\/\/go.drugbank.com\/drugs\/DB20752."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"105727","DOI":"10.18632\/oncotarget.22394","article-title":"MerTK inhibition by RXDX-106 in MerTK activated gastric cancer cell lines","volume":"8","author":"Kim","year":"2017","journal-title":"Oncotarget"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Tanaka, M., and Siemann, D.W. (2021). Therapeutic targeting of the Gas6\/Axl signaling pathway in Cancer. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22189953"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1158\/0008-5472.CAN-18-2022","article-title":"Immuno-oncological Efficacy of RXDX-106, a novel TAM (TYRO3, AXL, MER) family small-molecule kinase inhibitor","volume":"79","author":"Yokoyama","year":"2019","journal-title":"Cancer Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1158\/1078-0432.CCR-12-3459","article-title":"Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET","volume":"19","author":"Basilico","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Chilamakuri, R., and Agarwal, S. (2024). Repurposing of c-MET inhibitor tivantinib inhibits pediatric neuroblastoma cellular growth. Pharmaceuticals, 17.","DOI":"10.3390\/ph17101350"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e009690","DOI":"10.1136\/jitc-2024-009690","article-title":"Type I MET inhibitors cooperate with PD-1 blockade to promote rejection of hepatocellular carcinoma","volume":"12","author":"DeAzevedo","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1158\/0008-5472.CAN-12-3256","article-title":"Cytotoxic activity of Tivantinib (ARQ 197) is not due solely to c-MET inhibition","volume":"73","author":"Katayama","year":"2013","journal-title":"Cancer Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s40264-018-0780-x","article-title":"Safety and tolerability of c-MET inhibitors in cancer","volume":"42","author":"Puccini","year":"2019","journal-title":"Drug Saf."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Zhao, S., Wu, W., Jiang, H., Ma, L., Pan, C., Jin, C., Mo, J., Wang, L., and Wang, K. (2021). Selective inhibitor of the c-Met receptor tyrosine kinase in advanced hepatocellular carcinoma: No beneficial effect with the use of tivantinib?. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.731527"},{"key":"ref_107","unstructured":"(2026, June 10). Tivantinib: Uses, Interactions, Mechanism of Action\u2014DrugBank. Available online: https:\/\/go.drugbank.com\/drugs\/DB12200."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Hu, C.-T., Wu, J.-R., Cheng, C.-C., and Wu, W.-S. (2017). The therapeutic targeting of HGF\/c-Met signaling in hepatocellular carcinoma: Alternative approaches. Cancers, 9.","DOI":"10.3390\/cancers9060058"},{"key":"ref_109","first-page":"5574555","article-title":"Curcumin inhibits HGF-induced EMT by regulating c-MET-dependent PI3K\/Akt\/mTOR signaling pathways in meningioma","volume":"2021","author":"Chen","year":"2021","journal-title":"Evid.-Based Complement Altern. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.3892\/ol.2015.4063","article-title":"Curcumin mediates reversion of HGF-induced epithelial-mesenchymal transition via inhibition of c-Met expression in DU145 cells","volume":"11","author":"Hu","year":"2016","journal-title":"Oncol. Lett."},{"key":"ref_111","first-page":"4177","article-title":"Curcumin inhibits epithelial-mesenchymal transition in oral cancer cells via c-Met blockade","volume":"19","author":"Ohnishi","year":"2020","journal-title":"Oncol. Lett."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Akl, M.R., Ayoub, N.M., Mohyeldin, M.M., Busnena, B.A., Foudah, A.I., Liu, Y.-Y., and Sayed, K.A.E.I. (2014). Olive phenolics as c-Met inhibitors: (-)-Oleocanthal attenuates cell proliferation, invasiveness, and tumor growth in breast cancer models. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0097622"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"32247","DOI":"10.18632\/oncotarget.8681","article-title":"The oleocanthal-based homovanillyl sinapate as a novel c-Met inhibitor","volume":"7","author":"Mohyeldin","year":"2016","journal-title":"Oncotarget"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Tarun, M.T.I., Elsayed, H.E., Ebrahim, H.Y., and El Sayed, K.A. (2025). The olive oil phenolic S-(-)-oleocanthal suppresses colorectal cancer progression and recurrence by modulating SMYD2-EZH2 and c-MET activation. Nutrients, 17.","DOI":"10.3390\/nu17030397"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1080\/01635581.2017.1367936","article-title":"Rutin as a novel c-Met inhibitory lead for the control of triple negative breast malignancies","volume":"69","author":"Elsayed","year":"2017","journal-title":"Nutr. Cancer"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Hajimehdipoor, H., Tahmasvand, Z., Nejad, F.G., Maresca, M., and Rajabi, S. (2023). Rutin promotes proliferation and orchestrates epithelial-mesenchymal transition and angiogenesis in MCF-7 and MDA-MB-231 breast cancer cells. Nutrients, 15.","DOI":"10.3390\/nu15132884"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"105509","DOI":"10.1016\/j.bioorg.2021.105509","article-title":"Chamaejasmenin E from Stellera chamaejasme induces apoptosis of hepatocellular carcinoma cells by targeting c-Met in vitro and in vivo","volume":"119","author":"Yu","year":"2022","journal-title":"Bioorg. Chem."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Ji, J., Wang, Z., Sun, W., Li, Z., Cai, H., Zhao, E., and Cui, H. (2021). Effects of cynaroside on cell proliferation, apoptosis, migration and invasion though the MET\/AKT\/mTOR axis in gastric cancer. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222212125"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1021\/acsmedchemlett.1c00094","article-title":"Discovery of Potent, Selective Triazolothiadiazole-Containing c-Met Inhibitors","volume":"12","author":"Tang","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1039\/D4RA07556K","article-title":"Advances in pyrazolo[1,5-a]pyrimidines: Synthesis and their role as protein kinase inhibitors in cancer treatment","volume":"15","author":"Iorkula","year":"2025","journal-title":"RSC Adv."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1021\/acsmedchemlett.5c00713","article-title":"Molecular basis of c-MET inhibition by approved small molecule drugs: A structural perspective","volume":"17","author":"Russell","year":"2026","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.ejmech.2017.08.044","article-title":"Recent advances in the discovery of small molecule c-Met kinase inhibitors","volume":"143","author":"Parikh","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_123","first-page":"118509","article-title":"Novel 1-benzyl-2-indolinone indole hybrids as tyrosine kinase inhibitors: Design, synthesis, and biological activity evaluation","volume":"304","author":"Cinek","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"115675","DOI":"10.1016\/j.ejmech.2023.115675","article-title":"The mystery of titan hunter: Rationalized striking of the MAPK pathway via Newly synthesized 6-Indolylpyridone-3-Carbonitrile derivatives","volume":"259","author":"Saleh","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"128784","DOI":"10.1016\/j.bmcl.2022.128784","article-title":"Design, synthesis, in silico studies, and antiproliferative evaluations of novel indolin-2-one derivatives containing 3-hydroxy-4-pyridinone fragment","volume":"70","author":"Shirvani","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Karmacharya, U., Guragain, D., Chaudhary, P., Jee, J.-G., Kim, J.-A., and Jeong, B.-S. (2021). Novel pyridine bioisostere of cabozantinib as a potent c-Met kinase inhibitor: Synthesis and anti-tumor activity against hepatocellular carcinoma. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22189685"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"115499","DOI":"10.1016\/j.ejmech.2023.115499","article-title":"Design, synthesis and biological evaluation of 4-(4-aminophenoxy)picolinamide derivatives as potential antitumor agents","volume":"257","author":"Dai","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"106988","DOI":"10.1016\/j.bioorg.2023.106988","article-title":"Tailored horseshoe-shaped nicotinonitrile scaffold as dual promising c-Met and Pim-1 inhibitors: Design, synthesis, SAR and in silico study","volume":"143","author":"Mohamady","year":"2024","journal-title":"Bioorg. Chem."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4314\/bcse.v36i1.11","article-title":"Multi-component reactions of cyclohexan-1,3-dione to synthesize heterocyclic derivatives with c-Met enzymatic activity, anti-prostate, anti-proliferative and tyrosine kinase activities","volume":"36","author":"Mohareb","year":"2022","journal-title":"Bull. Chem. Soc. Ethiop."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"35003","DOI":"10.1039\/D5RA00553A","article-title":"Design, synthesis, and in silico studies of new benzofuran\u2013pyrazole hybrids as multi-kinase inhibitors with potential antiproliferative activity","volume":"15","author":"Syam","year":"2025","journal-title":"RSC Adv."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.14233\/ajchem.2023.28078","article-title":"Synthesis, characterization and evaluation of anticancer activity of new pyrazole-5-carboxamide derivatives","volume":"35","author":"Prathyusha","year":"2023","journal-title":"Asian J. Chem."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"118292","DOI":"10.1016\/j.bmc.2025.118292","article-title":"Design, synthesis, anticancer activity, and in silico computational studies of new imidazolone-based derivatives with potential multi-target kinase inhibitory activity","volume":"129","author":"Ahmed","year":"2025","journal-title":"Bioorg. Med. Chem."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"139074","DOI":"10.1016\/j.molstruc.2024.139074","article-title":"Design, synthesis and pharmacological evaluation of novel thiazole derivatives as c-Met kinase inhibitors and anticancer agents","volume":"1317","author":"Gediya","year":"2024","journal-title":"J. Mol. Struct."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"113648","DOI":"10.1016\/j.ejmech.2021.113648","article-title":"Structure-guided design and development of novel N-phenylpyrimidin-2-amine derivatives as potential c-Met inhibitors","volume":"223","author":"Huang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Mortazavi, M., Divar, M., Damghani, T., Moosavi, F., Saso, L., Pirhadi, S., Khoshneviszadeh, M., Edraki, N., and Firuzi, O. (2022). Study of the anticancer effect of new quinazolinone hydrazine derivatives as receptor tyrosine kinase inhibitors. Front. Chem., 10.","DOI":"10.3389\/fchem.2022.969559"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"e14502","DOI":"10.1111\/cbdd.14502","article-title":"Design, synthesis, and biological evaluation of novel quinoxaline aryl ethers as anticancer agents","volume":"103","author":"Nakka","year":"2024","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s13738-023-02956-x","article-title":"Anti-proliferative and morphological studies of 2-(benzo[d]thiazol-2-yl) derivatives together with their strategy in ionic liquids immobilized reactions","volume":"21","author":"Mohareb","year":"2024","journal-title":"J. Iran. Chem. Soc."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1007\/s11030-024-10998-3","article-title":"Design, synthesis and biological evaluation of thienopyridine derivatives as c-Met kinase inhibitors","volume":"29","author":"Xie","year":"2025","journal-title":"Mol. Divers."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"117634","DOI":"10.1016\/j.bmc.2024.117634","article-title":"1,3-Disubstituted-1,2,4-triazin-6-ones with potent activity against androgen receptor-dependent prostate cancer cells","volume":"101","author":"Zhao","year":"2024","journal-title":"Bioorg. Med. Chem."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"12889","DOI":"10.1039\/D3RA01931D","article-title":"New pyrazolopyridine and pyrazolothiazole-based compounds as anti-proliferative agents targeting c-Met kinase inhibition: Design, synthesis, biological evaluation, and computational studies","volume":"13","author":"Alamshany","year":"2023","journal-title":"RSC Adv."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"127740","DOI":"10.1016\/j.bmcl.2020.127740","article-title":"Design, synthesis and biological evaluation of novel 4-(pyrrolo[2,3-d]pyrimidine-4-yloxy)benzamide derivatives as potential antitumor agents","volume":"33","author":"Zhang","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"113273","DOI":"10.1016\/j.ejmech.2021.113273","article-title":"Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidine derivatives containing 1,8-naphthyridine-4-one fragment","volume":"215","author":"Zhang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"e202500447","DOI":"10.1002\/cmdc.202500447","article-title":"Recent insights in multi-target drugs in pharmacology and medicinal chemistry","volume":"20","author":"Cemali","year":"2025","journal-title":"ChemMedChem"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.cbpa.2020.05.009","article-title":"Two-hit wonders: The expanding universe of multitargeting epigenetic agents","volume":"57","author":"Ganesan","year":"2020","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"40363","DOI":"10.1038\/s41598-025-25796-6","article-title":"Antineoplastic 4-piperidone-1-phosphonothioates with potential multi-targeted inhibitory properties","volume":"15","author":"Bekheit","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"35018","DOI":"10.1038\/s41598-025-20712-4","article-title":"Antiproliferation, 3D-multicellular spheroid and VEGFR-2 inhibitory properties of spiroindolin-2-ones with phosphonate function","volume":"15","author":"Hassan","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/s41598-024-82005-6","article-title":"Design and synthesis of antiproliferative 2-oxoindolin-3-ylidenes incorporating urea function with potential VEGFR-2 inhibitory properties","volume":"15","author":"Aboshouk","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_148","unstructured":"(2026, June 10). Vandetanib: Uses, interactions, and mechanism of action\u2014BrugBank. Available online: https:\/\/go.drugbank.com\/drugs\/DB05294."},{"key":"ref_149","unstructured":"(2026, June 10). Vandetanib FDA approval history\u2014Drugs.com. Available online: https:\/\/www.drugs.com\/mtm\/vandetanib.html."},{"key":"ref_150","unstructured":"(2026, June 10). Sorafenib: Uses, Interactions, Mechanism of Action\u2014DrugBank. Available online: https:\/\/go.drugbank.com\/drugs\/DB00398."},{"key":"ref_151","unstructured":"(2026, June 10). Nexavar (Sorafenib) FDA Approval History\u2014Drugs.com. Available online: https:\/\/www.drugs.com\/history\/nexavar.html."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"12651","DOI":"10.1039\/D2NJ01561G","article-title":"Design, synthesis and biological evaluation of 4-phenoxy-pyridine\/pyrimidine derivatives as dual VEGFR-2\/c-Met inhibitors","volume":"46","author":"Yang","year":"2022","journal-title":"New J. Chem."},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Liu, X., Li, Y., Zhang, Q., Pan, Q., Zheng, P., Dai, X., Bai, Z., and Zhu, W. (2022). Design, synthesis, and biological evaluation of [1,2,4]triazolo[4,3-a] pyrazine derivatives as novel dual c-Met\/VEGFR-2 inhibitors. Front. Chem., 10.","DOI":"10.3389\/fchem.2022.815534"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.31788\/RJC.2022.1547094","article-title":"Dual targeting of VEGFR-2 AND c-MET kinases via the design and synthesis of substituted benzylidene-6-(5-chloropyrimidin-2-yl)-9H-purine-2,6-diamine derivatives as angiogenesis inhibitors","volume":"15","author":"More","year":"2022","journal-title":"Rasayan J. Chem."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cellsig.2018.07.010","article-title":"Advances in targeting epidermal growth factor receptor signaling pathway in mammary cancer","volume":"51","author":"Kyriakopoulou","year":"2018","journal-title":"Cell. Signal."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ccr.2014.02.025","article-title":"ERBB receptors: From oncogene discovery to basic science to mechanism-based cancer therapeutics","volume":"25","author":"Arteaga","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_157","unstructured":"(2026, June 10). Gefitinib: Uses, Interactions, Mechanism of Action\u2014DrugBank. Available online: https:\/\/go.drugbank.com\/drugs\/DB00317."},{"key":"ref_158","unstructured":"(2026, June 10). Iressa FDA Approval History,\u2014Drugs.com. Available online: https:\/\/www.drugs.com\/history\/iressa.html."},{"key":"ref_159","unstructured":"(2026, June 10). Erlotinib: Uses, Interactions, Mechanism of Action\u2014DrugBank. Available online: https:\/\/go.drugbank.com\/drugs\/DB00530."},{"key":"ref_160","unstructured":"(2026, June 10). Tarceva (Erlotinib) FDA Approval History\u2014Drugs.com. Available online: https:\/\/www.drugs.com\/history\/tarceva.html."},{"key":"ref_161","unstructured":"(2026, June 10). Afatinib: Uses, Interactions, Mechanism of Action. Available online: https:\/\/go.drugbank.com\/drugs\/DB08916."},{"key":"ref_162","unstructured":"(2026, June 10). Gilotrif (Afatinib) FDA Approval History. Available online: https:\/\/www.drugs.com\/history\/gilotrif.html."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"115939","DOI":"10.1016\/j.ejmech.2023.115939","article-title":"Design, synthesis, and biological evaluation of 4-(2-fluorophenoxy)-7-methoxyquinazoline derivatives as dual EGFR\/c-Met inhibitors for the treatment of NSCLC","volume":"263","author":"Tang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"106938","DOI":"10.1016\/j.bioorg.2023.106938","article-title":"Novel quinazoline-based dual EGFR\/c-Met inhibitors overcoming drug resistance for the treatment of NSCLC: Design, synthesis and anti-tumor activity","volume":"142","author":"Zhang","year":"2024","journal-title":"Bioorg. Chem."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.1021\/acs.jmedchem.8b01469","article-title":"Cyclin-dependent kinase 2 inhibitors in cancer therapy: An update","volume":"62","author":"Tadesse","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"105922","DOI":"10.1016\/j.bioorg.2022.105922","article-title":"Novel indazole derivatives as potent apoptotic antiproliferative agents by multi-targeted mechanism: Synthesis and biological evaluation","volume":"126","author":"Frejat","year":"2022","journal-title":"Bioorg. Chem."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"118164","DOI":"10.1016\/j.ejmech.2025.118164","article-title":"Discovery of a novel benzofuran-7-carboxamide-based PARP1\/c-Met dual inhibitor for addressing c-Met amplification-mediated PARP1i acquired-resistance","volume":"300","author":"Sun","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"ref_168","unstructured":"(2026, June 10). Lynparza (Olaparib) FDA Approval History. Available online: https:\/\/www.drugs.com\/history\/lynparza.html."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"130415","DOI":"10.1016\/j.bmcl.2025.130415","article-title":"Design, synthesis, and biological evaluation of novel potent dual Mer\/c-Met inhibitors based on structural optimization","volume":"130","author":"Duan","year":"2026","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Huang, D., Chen, Y., Yang, J., Zhao, B., Wang, S., Chai, T., Cui, J., Zhou, X., and Shang, Z. (2024). Design, synthesis, and biological evaluation of 2-substituted aniline pyrimidine derivatives as potent dual Mer\/c-Met inhibitors. Molecules, 29.","DOI":"10.3390\/molecules29020475"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1007\/s11030-024-10807-x","article-title":"Design, synthesis, and biological evaluation of new biaryl derivatives of cycloalkyl diacetamide bearing chalcone moiety as type II c-MET kinase inhibitors","volume":"28","author":"Salarinejad","year":"2024","journal-title":"Mol. Divers."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"108187","DOI":"10.1016\/j.bioorg.2025.108187","article-title":"Identification of a 7H-pyrrolo[2,3-d]pyrimidin derivatives as selective type II c-Met\/Axl inhibitors with potent antitumor efficacy","volume":"156","author":"Qin","year":"2025","journal-title":"Bioorg. Chem."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"104178","DOI":"10.1016\/j.drudis.2024.104178","article-title":"Targeted protein degradation: Current molecular targets, localization, and strategies","volume":"29","author":"Pliatsika","year":"2024","journal-title":"Drug Discov. Today"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/d41573-021-00052-4","article-title":"Targeted protein degraders crowd into the clinic","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrd.2016.211","article-title":"Induced protein degradation: An emerging drug discovery paradigm","volume":"16","author":"Lai","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: The past is prologue","volume":"21","author":"Langley","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ddtec.2019.01.002","article-title":"PROteolysis TArgeting Chimeras (PROTACs): Past, present and future","volume":"31","author":"Pettersson","year":"2019","journal-title":"Drug Discov. Today Technol."},{"key":"ref_178","first-page":"725","article-title":"Proteolysis targeting chimeras (PROTACs) come of age: Entering the third decade of targeted protein degradation","volume":"2","author":"Bond","year":"2021","journal-title":"RSC Med. Chem."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cell.2020.12.020","article-title":"The rise of molecular glues","volume":"184","author":"Schreiber","year":"2021","journal-title":"Cell"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41586-020-2545-9","article-title":"Lysosome-targeting chimaeras for degradation of extracellular proteins","volume":"584","author":"Banik","year":"2020","journal-title":"Nature"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.molcel.2019.09.009","article-title":"AUTACs: Cargo-specific degraders using selective autophagy","volume":"76","author":"Takahashi","year":"2019","journal-title":"Mol. Cell"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41586-019-1722-1","article-title":"Allele-selective lowering of mutant HTT protein by HTT\u2013LC3 linker compounds","volume":"575","author":"Li","year":"2019","journal-title":"Nature"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/18\/8007\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T09:30:38Z","timestamp":1788946238000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/18\/8007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":182,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["ijms27188007"],"URL":"https:\/\/doi.org\/10.3390\/ijms27188007","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]}}}